Inspiring Scientific Discovery
Search hundreds of thousands of products backed by our one-year, replacement or money-back, satisfaction guarantee.
Bioss 10th Anniversary Promotion
Come check out our giveaway to celebrate 10 years of Bioss supporting scientific discoveries
Bioss COVID-19 Products
The ultimate goal of Bioss is to improve the health and quality of life of humans and animals. To fight against COVID-19, Bioss has developed antibodies, proteins, and the ELISA kit in support of studies on the novel coronavirus.
Current Promotions
Enter here to see a listing of our current promotions running until the end of June 2022!
Pennybody Promotion
Haven't worked with Bioss Antibodies before? Try one of our 20uL trial-sized vials for just $0.01 plus shipping. Click here to view program details and to request your discount code for this promotional pricing.
Bioss Blog: the conversation with sciences
Bioss developed a matched antibody pair to efficiently detect Omicron Nucleocapsid proteinsA large number of studies showed that the nucleocapsid protein (N protein) of SARS-CoV-2 is expressed abundantly during infection and is extremely immunogenic, so many rapid at-home antigen tests were designed by using N protein as an antibody target. However, the concern is coming with the many mutations in Omicron N proteins, i.e., Omicron variant may dampen the accuracy of current available rapid at-home antigen tests.
What are PROTACs and How Do They Treat Diseases?Around 80% of disease-causing proteins, including key drivers of many cancers and other serious neurological conditions like Alzheimer’s disease, cannot be targeted by currently available therapeutics. These so-called “undruggable” proteins lack specific surface areas required for treatments such as small molecule inhibitors or antibodies to bind with disease-causing proteins and modulate their function.
A cohort study on the long-term effectiveness of Pfizer mRNA vaccine in the USASince the delta variant of the novel coronavirus has spread in the United States, more and more breakthrough cases (still infected after vaccination) caught people's attention, and a concern that the protective effect of the new mRNA vaccine is getting weaker was raised. To address this question, we must determine whether these breakthrough infections were driven by the delta mutant strain, or were they due to the decline of immunity per se?
Bioss Pathway Maps
Diving into a new project? Get up to speed quickly with these cellular and molecular pathway maps. Each one is expertly researched and hand-drawn by our scientific team. Autophagy, Tumor Immunology, MAPK, WNT Signaling, and many others are available to download, print, and share at your convenience.
About Us
Bioss Inc is a leading antibody developer and manufacturer with state of the art technologies. We have developed over 11,000 primary antibodies and more than 130,000 derived products including fluorochrome conjugated antibodies. In addition to reliable loading control and tag antibodies, our catalog includes over 1000 specific antibodies recognizing proteins with phosphorylation, acetylation, or methylation modifications.